USANew treatments and approvals
Obinutuzumab approved in the USA for kidney inflammation caused by lupus
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA approved obinutuzumab as an add-on to standard treatment in adults with active lupus nephritis. The approval is based on a phase 3 study of 271 patients. At week 76, complete kidney response was 46.4% in the drug group and 33.1% in the placebo group. Serious infections were slightly more common in the drug group. The drug is given intravenously.
What does it mean for patients and families?
A new option to protect the kidneys in lupus nephritis has been approved in the USA. Access in Türkiye for this use depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with a doctor.
Source
ABD Gıda ve İlaç Dairesi (FDA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Systemic lupus erythematosus (SLE)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.